Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Shares Outstanding (2021 - 2025)

Historic Shares Outstanding for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $1.6 million.

  • Lyra Therapeutics' Shares Outstanding rose 2561.41% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 2561.41%. This contributed to the annual value of $1.3 million for FY2024, which is 1450.83% up from last year.
  • Per Lyra Therapeutics' latest filing, its Shares Outstanding stood at $1.6 million for Q3 2025, which was up 2561.41% from $1.6 million recorded in Q2 2025.
  • Lyra Therapeutics' Shares Outstanding's 5-year high stood at $49.5 million during Q3 2023, with a 5-year trough of $1.1 million in Q4 2023.
  • In the last 5 years, Lyra Therapeutics' Shares Outstanding had a median value of $13.0 million in 2021 and averaged $15.9 million.
  • As far as peak fluctuations go, Lyra Therapeutics' Shares Outstanding surged by 14479.73% in 2022, and later crashed by 9735.77% in 2024.
  • Quarter analysis of 5 years shows Lyra Therapeutics' Shares Outstanding stood at $13.0 million in 2021, then surged by 144.69% to $31.8 million in 2022, then plummeted by 96.4% to $1.1 million in 2023, then increased by 14.51% to $1.3 million in 2024, then increased by 25.5% to $1.6 million in 2025.
  • Its Shares Outstanding was $1.6 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.3 million in Q1 2025.